PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31833548-5	2020	To clarify the mechanisms that mutant isocitrate dehydrogenase (IDH) affect the intraoperative fluorescence, in Vitro experiments using genetically engineered glioma cells harboring mutant IDH1 were performed.	Isocitrates	38-48	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	64-67
31847543-7	2020	CRITICAL ISSUES: Typically heterozygous mutations within the active sites of isocitrate dehydrogenase IDH1R132H and mitochondrial IDH2R140Q provide cells with millimolar R-2HG concentrations, while side-activities of lactate and malate dehydrogenase form submillimolar S-2HG.	Isocitrates	77-87	malic enzyme 2	Homo sapiens	229-249
32003035-1	2020	PURPOSE: To generate a preclinical model of isocitrate dehydrogenase (IDH) mutant gliomas from glioma patients and design a MRS method to test the compatibility of 2-hydroxyglutarate (2HG) production between the preclinical model and patients.	Isocitrates	44-54	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	70-73
32027343-1	2020	Importance: Per the World Health Organization 2016 integrative classification, newly diagnosed glioblastomas are separated into isocitrate dehydrogenase gene 1 or 2 (IDH)-wild-type and IDH-mutant subtypes, with median patient survival of 1.2 and 3.6 years, respectively.	Isocitrates	128-138	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	166-169
31637414-1	2020	BACKGROUND: The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) WHO grade II or III that present with a) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or b) gain of chromosome 7 combined with loss of chromosome 10, and/or c) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV).	Isocitrates	129-139	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	172-180
31637414-1	2020	BACKGROUND: The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) WHO grade II or III that present with a) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or b) gain of chromosome 7 combined with loss of chromosome 10, and/or c) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV).	Isocitrates	129-139	epidermal growth factor receptor	Homo sapiens	400-432
31637414-1	2020	BACKGROUND: The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) WHO grade II or III that present with a) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or b) gain of chromosome 7 combined with loss of chromosome 10, and/or c) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV).	Isocitrates	129-139	epidermal growth factor receptor	Homo sapiens	434-438
31637414-1	2020	BACKGROUND: The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) WHO grade II or III that present with a) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or b) gain of chromosome 7 combined with loss of chromosome 10, and/or c) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV).	Isocitrates	129-139	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	172-176
31637414-1	2020	BACKGROUND: The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) WHO grade II or III that present with a) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or b) gain of chromosome 7 combined with loss of chromosome 10, and/or c) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV).	Isocitrates	129-139	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	172-178
32025842-5	2020	Isocitrate dehydrogenase inhibitors (IDH) constitute another therapeutic class with DNA methylation effects in AML.	Isocitrates	0-10	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	37-40
32059860-10	2020	All studied milk metabolites were significantly correlated with energy balance (Spearman correlation = 0.48, 0.63, -0.31, -0.45, and 0.61 for BHB, glucose, glucose-6-phosphate, isocitrate, and glutamate, respectively).	Isocitrates	177-187	Weaning weight-maternal milk	Bos taurus	12-16
31863529-3	2020	N-terminal proline exists in more than 300 proteins in Saccharomyces cerevisiae, but only three of them are the gluconeogenic enzymes; isocitrate lyase (Icl1), fructose-1,6-bisphosphatase (Fbp1), and malate dehydrogenase (Mdh2).	Isocitrates	135-145	isocitrate lyase 1	Saccharomyces cerevisiae S288C	153-157
31894617-3	2020	The transition from immune resistance to tolerance also diverts the TCA cycle from citrate-derived cis-aconitate to itaconate, a recently discovered catabolic mediator that separates the TCA cycle at isocitrate and succinate dehydrogenase (SDH).	Isocitrates	200-210	aminoadipate-semialdehyde synthase	Mus musculus	240-243
32076999-4	2020	The relationship between DPP4 levels, WHO pathological grade gliomas, and isocitrate dehydrogenase 1 and 2 (IDH1/2) status was assessed in patient samples.	Isocitrates	74-84	dipeptidyl peptidase 4	Homo sapiens	25-29
32071674-1	2020	Inhibitors of mutant isocitrate dehydrogenase (mIDH) 1 and 2 cancer-associated enzymes prevent the accumulation of the oncometabolite d-2-hydroxyglutarate (2-HG) and are under clinical investigation for the treatment of several cancers harboring an IDH mutation.	Isocitrates	21-31	isocitrate dehydrogenase 1 (NADP+), soluble	Mus musculus	48-51
32015410-1	2020	Isocitrate dehydrogenase 2 (IDH2) is an NADP+-dependent enzyme that catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate in the mitochondrial matrix, and is critical for the production of NADPH to limit the accumulation of mitochondrial reactive oxygen species (ROS).	Isocitrates	111-121	isocitrate dehydrogenase 2 (NADP+), mitochondrial	Mus musculus	0-26
32015410-1	2020	Isocitrate dehydrogenase 2 (IDH2) is an NADP+-dependent enzyme that catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate in the mitochondrial matrix, and is critical for the production of NADPH to limit the accumulation of mitochondrial reactive oxygen species (ROS).	Isocitrates	111-121	isocitrate dehydrogenase 2 (NADP+), mitochondrial	Mus musculus	28-32
31586149-1	2020	Mutations in isocitrate dehydrogenase 1 (IDH1) are found in 6% of AML patients.	Isocitrates	13-23	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	41-45
31865175-1	2020	The isocitrate dehydrogenase (IDH1/2) mutations are frequent genetic abnormalities in the majority of WHO grade II/III glioma and secondary GBM.	Isocitrates	4-14	isocitrate dehydrogenase 1 (NADP+), soluble	Mus musculus	30-36
31871049-3	2020	Using mass spectrometry and chemical analysis, we identified marked changes of intermediate metabolites in ACE over expressing macrophages and neutrophils, with increased cellular ATP (1.7- to 3.0-fold) and Krebs cycle intermediates including citrate, isocitrate, succinate, and malate (1.4- to 3.9-fold).	Isocitrates	252-262	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	107-110
31726354-8	2020	A trend showed that tumours associated with poorer outcomes (recurrent tumours and Isocitrate Dehydrogenase - IDH wildtype) displayed higher viability on chip than tumours linked with improved outcomes (low-grade gliomas, IDH mutants and primary tumours).	Isocitrates	83-93	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	110-113
31963507-14	2020	In line with this finding, the expression levels for TSPO and AIF1 were also significantly higher in (isocitrate-dehydrogenase wild-type) IDHWT compared to IDH mutant (IDHMUT) GBM.	Isocitrates	102-112	translocator protein	Homo sapiens	53-57
31963507-14	2020	In line with this finding, the expression levels for TSPO and AIF1 were also significantly higher in (isocitrate-dehydrogenase wild-type) IDHWT compared to IDH mutant (IDHMUT) GBM.	Isocitrates	102-112	allograft inflammatory factor 1	Homo sapiens	62-66
31963507-14	2020	In line with this finding, the expression levels for TSPO and AIF1 were also significantly higher in (isocitrate-dehydrogenase wild-type) IDHWT compared to IDH mutant (IDHMUT) GBM.	Isocitrates	102-112	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	138-141
31935911-2	2020	Mutations in isocitrate dehydrogenase enzymes (IDH1/2) were recently described in several cancers, including conventional and dedifferentiated chondrosarcomas.	Isocitrates	13-23	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	47-53
31908598-9	2020	An increased success rate of implantation in gliomas with wild type isocitrate dehydrogenase (IDH) and high Ki67 expression was observed compared to gliomas with mutant IDH and low Ki67 expression.	Isocitrates	68-78	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	94-97
31714193-0	2020	MRI and CT Identify Isocitrate Dehydrogenase (IDH)-Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization.	Isocitrates	20-30	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	46-49
31929772-3	2020	For example, D-2-hydroxyglutarate, generated due to the activity of mutated mitochondrial isocitrate dehydrogenase (IDH), has been implicated in the pathogenesis of leukemia.	Isocitrates	90-100	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	116-119
31969485-1	2020	Gliomas that express the mutated isoforms of isocitrate dehydrogenase 1/2 (IDH1/2) have better prognosis than wild-type (wt) IDH1/2 gliomas.	Isocitrates	45-55	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	75-81
31969485-1	2020	Gliomas that express the mutated isoforms of isocitrate dehydrogenase 1/2 (IDH1/2) have better prognosis than wild-type (wt) IDH1/2 gliomas.	Isocitrates	45-55	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	125-131
32055803-1	2020	Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to alpha-ketoglutarate (alphaKG).	Isocitrates	88-98	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	34-38
32055803-1	2020	Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to alpha-ketoglutarate (alphaKG).	Isocitrates	88-98	isocitrate dehydrogenase (NADP(+)) 2	Homo sapiens	43-47
31907132-1	2019	Objective To investigate the clinical value of serum tumor marker isocitrate dehydrogenase 1(IDH1)in the diagnosis of lung cancer.	Isocitrates	66-76	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	93-97
31921684-1	2019	Objectives: In the present study, we aimed to determine the candidate genes that may function as biomarkers to further distinguish patients with isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GBM), which are heterogeneous with respect to clinical outcomes.	Isocitrates	145-155	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	171-174
31888244-2	2019	IDH1wt converts isocitrate to alpha-ketoglutarate while reducing nicotinamide adenine dinucleotide phosphate (NADP+), whereas IDH1R132H uses alpha-ketoglutarate and NADPH to generate the oncometabolite 2-hydroxyglutarate (2-HG).	Isocitrates	16-26	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	0-4
31810230-1	2019	Chondrosarcomas are chemo- and radiotherapy resistant and frequently harbor mutations in isocitrate dehydrogenase (IDH1 or IDH2), causing increased levels of D-2-hydroxyglutarate (D-2-HG).	Isocitrates	89-99	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	115-119
31810230-1	2019	Chondrosarcomas are chemo- and radiotherapy resistant and frequently harbor mutations in isocitrate dehydrogenase (IDH1 or IDH2), causing increased levels of D-2-hydroxyglutarate (D-2-HG).	Isocitrates	89-99	isocitrate dehydrogenase (NADP(+)) 2	Homo sapiens	123-127
31795195-2	2019	KRAS/NRAS mutations are common in ICC tumours and 6-32% of patients also have isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) gene mutations associated with metabolic changes.	Isocitrates	78-88	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	112-116
31921378-1	2019	This case report aimed to review the bone marrow features of patients with acute myeloid leukemia (AML) treated with isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors.	Isocitrates	117-127	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	147-153
31795195-2	2019	KRAS/NRAS mutations are common in ICC tumours and 6-32% of patients also have isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) gene mutations associated with metabolic changes.	Isocitrates	78-88	isocitrate dehydrogenase (NADP(+)) 2	Homo sapiens	121-125
31632056-0	2019	Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCRTM In Patients With AML And Their Clinical Impact In Mexico City.	Isocitrates	30-40	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	62-66
31660152-1	2019	Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to alpha-ketoglutarate (alpha-KG) in the tricarboxylic acid (TCA) cycle.	Isocitrates	77-87	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	0-24
31660152-1	2019	Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to alpha-ketoglutarate (alpha-KG) in the tricarboxylic acid (TCA) cycle.	Isocitrates	77-87	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	26-29
31742037-12	2019	Mutations in gene encoding isocitrate dehydrogenase 1 and 2 (IDH 1&2) occur in some enchondromas and spindle cell hemangiomas.	Isocitrates	27-37	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	61-66
31694539-1	2019	BACKGROUND: Isocitrate lyase (ICL) is a key enzyme in the glyoxylate cycle.	Isocitrates	12-22	isocitrate lyase	Arabidopsis thaliana	30-33
31632056-0	2019	Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCRTM In Patients With AML And Their Clinical Impact In Mexico City.	Isocitrates	30-40	isocitrate dehydrogenase (NADP(+)) 2	Homo sapiens	67-71
31632056-2	2019	A variety of mutations have been identified at the molecular level, such as those in the IDH1/2 gene, which causes a gain of function of the isocitrate dehydrogenase enzyme, generating high levels of the (R)-2-hydroxyglutarate oncometabolite, which competitively inhibits dioxygenase enzymes.	Isocitrates	141-151	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	89-95
31546946-1	2019	Mitochondrial nicotinamide adenine dinucleotide phosphate (NADP+)-dependent isocitrate dehydrogenase (IDH2) plays a key role in the intermediary metabolism and energy production via catalysing oxidative decarboxylation of isocitrate to alpha-ketoglutarate in the tricarboxylic acid (TCA) cycle.	Isocitrates	76-86	isocitrate dehydrogenase 2 (NADP+), mitochondrial	Mus musculus	102-106
31546946-1	2019	Mitochondrial nicotinamide adenine dinucleotide phosphate (NADP+)-dependent isocitrate dehydrogenase (IDH2) plays a key role in the intermediary metabolism and energy production via catalysing oxidative decarboxylation of isocitrate to alpha-ketoglutarate in the tricarboxylic acid (TCA) cycle.	Isocitrates	222-232	isocitrate dehydrogenase 2 (NADP+), mitochondrial	Mus musculus	102-106